Deal or Case news
On 14 August 2020, CureVac NV launched a successful IPO on the Nasdag Global Market, raising USD 213 million. The company raised a further USD 118 million in a private placement and recently completed a USD 640 million private financing round.

These three transactions collectively represent equity investments of more than USD one billion. NautaDutilh acted as Dutch counsel to CureVac for the private financing round, the IPO and the private placement, alongside Davis Polk & Wardwell (US counsel) and Rittershaus (German counsel).

CureVac is a clinical-stage biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), including an mRNA vaccine for the novel coronavirus that causes Covid-19.

NautaDutilh is proud to have been able to help CureVac reach this important milestone.

Related articles

Cookie notification

This functionality uses third-party cookies. Change your cookie preferences to view this content or view more information.
These cookies ensure that the website works properly. These cookies cannot be disabled.
These cookies can be placed by third parties, such as YouTube or Vimeo.
By deactivating categories, it is possible that related functionalities within the website may no longer work properly. It is always possible to change your preferences at a later time. View more information.